Literature DB >> 9533549

Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.

T Vogt1, W Stolz, J Welsh, B Jung, R S Kerbel, H Kobayashi, M Landthaler, M McClelland.   

Abstract

The Lerks, ligands of eph-related receptor tyrosine kinases, are a rapidly expanding family of genes thought to play an important role in the development and oncogenesis of various tissues. However, very little experimental evidence supports this hypothesis. Using RNA fingerprinting, we detected increased expression of Lerk-5 mRNA in human melanocytes as a response to the tumor-promoting drug 12-O-tetradecanoylphorbol-13-acetate, which suggests a possible role of the Lerks in melanoma tumorigenesis and progression. Therefore, we studied Lerk-5 mRNA expression in various melanoma cell lines and tissues of melanocytic tumors by semiquantitative reverse transcription-PCR. Modest expression of Lerk-5 mRNA was found in two melanoma cell lines derived from early primary tumors (WM35 and WM1645B); two metastatic cell lines tested showed a 3.9-fold increased transcript abundance when compared to the primary cell lines (RPMI-7951 and SK-Mel5). Progeny of a melanoma cell line with very low Lerk-5 mRNA abundance (WM35) showed a 5-fold increase in Lerk-5 mRNA expression when it was selected for higher tumorigenicity and multicytokine resistance by passaging in nude mice or repeated high-dose UVB irradiation. Consistent with these experimental data, we found high levels of Lerk-5 mRNA expression in advanced primary malignant melanomas and metastases (n = 22) but significantly lower or undetectable mRNA expression in benign melanocytic nevi (n = 9; P < 0.001). We conclude that increased Lerk-5 expression possibly reflects or induces an increased potential of growth, tumorigenicity, and metastatic abilities in human melanomas. This makes the yet to be elucidated eph-related receptor tyrosine kinase/Lerk signaling system a potential new source for molecular markers as well as a target for new therapies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533549

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

Review 1.  [Role of receptor tyrosine kinase in the angiogenesis].

Authors:  S Meyer; C Hafner; T Vogt
Journal:  Hautarzt       Date:  2002-09       Impact factor: 0.751

2.  Kinetic analysis of the binding of monomeric and dimeric ephrins to Eph receptors: correlation to function in a growth cone collapse assay.

Authors:  Kumar B Pabbisetty; Xin Yue; Chen Li; Juha-Pekka Himanen; Renping Zhou; Dimitar B Nikolov; Longqin Hu
Journal:  Protein Sci       Date:  2007-03       Impact factor: 6.725

3.  EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion.

Authors:  Mitsutoshi Nakada; Jared A Niska; Nhan L Tran; Wendy S McDonough; Michael E Berens
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

Review 4.  Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling.

Authors:  Dana M Brantley-Sieders
Journal:  Semin Cell Dev Biol       Date:  2011-10-21       Impact factor: 7.727

5.  Melanoma revives an embryonic migration program to promote plasticity and invasion.

Authors:  Caleb M Bailey; Jason A Morrison; Paul M Kulesa
Journal:  Pigment Cell Melanoma Res       Date:  2012-08-02       Impact factor: 4.693

6.  Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma.

Authors:  X X Tang; H Zhao; M E Robinson; B Cohen; A Cnaan; W London; S L Cohn; N K Cheung; G M Brodeur; A E Evans; N Ikegaki
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

7.  EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.

Authors:  Wang Xuqing; Cui Lei; Mao Zhengfa; Dang Shengchun; Fan Xin; Qu Jianguo; Zhang Jianxin
Journal:  Tumour Biol       Date:  2012-04-24

8.  ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias.

Authors:  Hiroshi Nakanishi; Tatsuya Nakamura; Eli Canaani; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

9.  Inhibition of tumor growth and angiogenesis by soluble EphB4.

Authors:  Georg Martiny-Baron; Thomas Korff; Florence Schaffner; Norbert Esser; Stefan Eggstein; Dieter Marmé; Hellmut G Augustin
Journal:  Neoplasia       Date:  2004 May-Jun       Impact factor: 5.715

10.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.